Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arca Biopharma Inc (ABIO)

Arca Biopharma Inc (ABIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,057
  • Shares Outstanding, K 9,321
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,480 K
  • 60-Month Beta 2.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.79
Trade ABIO with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.73 +12.33%
on 11/20/20
4.45 -5.84%
on 11/27/20
+0.16 (+3.97%)
since 11/04/20
3-Month
3.71 +12.94%
on 10/30/20
5.49 -23.68%
on 09/15/20
-0.22 (-4.99%)
since 09/04/20
52-Week
2.21 +89.59%
on 03/19/20
22.00 -80.95%
on 05/28/20
-1.14 (-21.39%)
since 12/04/19

Most Recent Stories

More News
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the...

ABIO : 4.19 (-1.64%)
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial...

ABIO : 4.19 (-1.64%)
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

-- Initiation of Phase 2b clinical trial anticipated in Q4 2020

ABIO : 4.19 (-1.64%)
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the promotion...

AMGN : 229.21 (+1.01%)
ABIO : 4.19 (-1.64%)
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has...

ABIO : 4.19 (-1.64%)
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19

ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as Q4 2020

ABIO : 4.19 (-1.64%)
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update

-- ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020

ABIO : 4.19 (-1.64%)
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering

ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced...

ABIO : 4.19 (-1.64%)
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More

The biotech sector remains in focus with updates on coronavirus treatments and presentations at ASCO.

IRWD : 11.98 (+3.45%)
REGN : 492.45 (-1.28%)
GILD : 61.56 (+1.15%)
ABIO : 4.19 (-1.64%)
NTLA : 43.44 (+1.21%)
PHAS : 4.24 (+3.67%)
ARCA Biopharma Announces $9.4 Million Registered Direct Offering

ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced...

ABIO : 4.19 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular...

See More

Key Turning Points

2nd Resistance Point 4.36
1st Resistance Point 4.28
Last Price 4.19
1st Support Level 4.14
2nd Support Level 4.08

See More

52-Week High 22.00
Fibonacci 61.8% 14.44
Fibonacci 50% 12.10
Fibonacci 38.2% 9.77
Last Price 4.19
52-Week Low 2.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar